oncology-cancer-therapy-2019-posters-abstracts

16 / 17

Page 53
allied
academies
Journal of Medical Oncology & Therapeutics | Volume 4
March 18-19, 2019 | London, UK
Oncology & Cancer Therapy
International Conference on
Effective number of cycle and dose in metastatic castrated resistant prostatic cancer in Sudanese patient
Ehssan M Alnazir Ahmed
Omdurman Islamic university, Sudan
Background: Prostate cancer remain the most common
cancer in men worldwide. The initial treatment of choice for
prostate cancer is androgen deprivation. if resistant develop
then Docetaxel becomes the mainstay therapy for patients
with metastatic castrated resistant prostate cancer.
Objectives: To evaluate the benefit of docetaxel in patients
with metastatic castrated resistant prostate cancer (mCRPC)
after initial good response to first line hormonal therapy.
To determine the effective number of cycles and doses of
doectaxel.
Research methodology: Study design; analytic retrospective
study, Duration; 2017-2013, Area; radioisotope center of
Khartoum ( RICK ), Population; (mCRPC). Data collection; RICK
record, Inclusion criteria; any prostatic cancer patient become
castrated resistant and now on docetaxel therapy
Procedure: Patient files, Sample size; 60 patients.
Conclusion: We retrospectively collected 60 patients receiving
varying numbers of docetaxel plus prednislone and analyzed
the clinical outcomes including performance status, prostate-
specific antigen (PSA) response and pain. According to this study
we found that docetaxel has effective role in the treatment of
mCRPC patients with optimal number of cycles 6 to 8 every 3
weeks and dose of 75mg.
e:
Notes: